SCHEMBL263791

SCHEMBL263791

Cc1oncc1C(=O)Nc1ccc(-c2ccccc2Cl)c(N)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 11/20 0.60
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
SCN9A Q15858 3/20 0.46
SCN5A Q14524 2/20 0.46
SCN2A Q99250 2/20 0.46
SCN3A Q9NY46 2/20 0.46
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
SCN1A P35498 1/20 0.43
LMNA P02545 2/20 0.41
ALDH1A1 P00352 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
GMNN O75496 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14237281 0.87 SCN10A (0.61) SCN10ANPC1RAB9ASCN9ASCN5A
SCHEMBL2415327 0.85 SCN10A (0.50) SCN10ANPC1RAB9ATDP1MEN1
SCHEMBL14237342 0.84 SCN10A (0.69) SCN10ANPC1RAB9ASCN9ASCN5A
SCHEMBL264402 0.84 SCN10A (0.54) SCN10ANPC1RAB9ASCN9ASCN5A
SCHEMBL263563 0.82 SCN10A (0.70) SCN10ANPC1RAB9ASCN9ASCN5A
SCHEMBL263424 0.80 SCN10A (0.73) SCN10ANPC1RAB9ASCN9ASCN5A
SCHEMBL14237526 0.79 SCN10A (0.63) SCN10ANPC1SCN9ASCN5ASCN2A
SCHEMBL14237737 0.78 SCN10A (0.64) SCN10ANPC1RAB9ASCN9ASCN5A
SCHEMBL4211450 0.77 SCN10A (0.47) SCN10ASCN9ASCN5ASCN2ASCN3A
SCHEMBL14237552 0.77 SCN10A (0.61) SCN10ASCN9ASCN5ASCN2ASCN3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP claimed
US-8134007-B2 Pyridine derivatives PFIZER INC. (US) 2012-03-13 US claimed
JP-4657384-B2 2011-03-23 JP claimed
JP-2010526050-A 2010-07-29 JP claimed
EP-2183241-A2 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS Pfizer Limited (GB) 2010-05-12 EP claimed
US-20090048306-A1 PYRIDINE DERIVATIVES PFIZER, INC. (US) 2009-02-19 US claimed
WO-2008135826-A2 2 -PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LIMITED (GB) 2008-11-13 WO claimed
EP-2183241-B1 2-PYRIDINE CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS PFIZER LTD (GB) 2012-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048306-A1 PYRIDINE DERIVATIVES SDHA, P2RX4, P2RX3 SCN10A 358/4885NPC1 2285/4885RAB9A 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.